Mitsubishi Pharma Corporation

The Kitasato Institute

Aphoenix, Inc.

Haruko Yamabe

Satoshi Omura

Toshiaki Sunazuka

Akira Nakao

Masahiro Okuyama

Kenichiro Nagai

Mitsuru Ooizumi

Hideaki Shima

Ken-ichi Saito

Takayuki Ishige

A compound represented by the formula [I] wherein each symbol is as defined in the specification or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing the compound as an active ingredient. 

Dihydropseudoerythromycin derivatives

Novel compounds represented by the following formula (I) that act as a ligand to sigma receptor/binding cite and a medicament comprising the same as an active ingredient: wherein X represents an alkyl group, an aryl group, a heterocyclic group or the like; Q represents a group represented by &#x2014;CH&#x2014;, &#x2014;CO&#x2014;, &#x2014;O&#x2014;, &#x2014;CH(OR)&#x2014; or the like wherein Rrepresents a hydrogen atom, an alkyl group or the like; n represents an integer of from 0 to 5; Rand Reach represent a hydrogen atom, an alkyl group or the like; B represents either of the following groups: wherein R, R, R, and Reach represent a hydrogen atom, a halogen atom, an alkoxyl group or the like; m represents 1 or 2; and the ring of: represents an aromatic heterocyclic ring.

Cyclic amide derivatives

The invention relates to novel polymorph crystal forms A and B of N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide: The compounds and pharmaceutical compositions thereof are useful for activating a malfunctioned cholinergic neuron that is associated with memory loss disturbances.

Polymorph forms of N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-B]quinolin-4-YL)-2-(2-oxopyrrolidin-1-YL)acetamide

Growing community of inventors

Tokyo, Japan

Haruko Yamabe